Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)



Status:Active, not recruiting
Conditions:Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:65 - Any
Updated:9/26/2018
Start Date:September 13, 2017
End Date:December 2027

Use our guide to learn which trials are right for you!

Empowering Medicare Patients to Self-Manage Their Type 2 Diabetes Using Continuous Glucose Monitoring (CGM) - Investigational Device Pilot (SMA Investigational Device)

This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor
(CGM) as part of an educational program designed to help them better manage their glucose
levels. Subjects will also wear an activity tracker to monitor their activity and observe its
effect on their glucose levels. The educational program will involve calls from coaches to
check subjects' progress and answer questions.


Inclusion Criteria:

- Be diagnosed with type 2 diabetes

- Be able to read and understand English

- Have access to a telephone

- Have a Medicare Advantage health plan through Senior Dimensions

Exclusion Criteria:

- Pregnant

- Blind

- Deaf

- Receiving chemotherapy or radiation to treat cancer (now or in past 6 months)

- Misusing any drugs (including alcohol, painkillers, hallucinogens, or others)

- Critically ill

- Diagnosed with or experiencing:

- Kidney disease stages 4 and 5

- End stage renal disease

- Severe liver disease

- Dementia

- Schizophrenia

- Bipolar disorder

- Autism

- An intellectual or learning disability

- Arrhythmias other than atrial fibrillation

- Congestive heart failure

- Has had a:

- Myocardial infarction within the last 6 months

- Stroke within the last 6 months

- Stroke that resulted in significant disability (e.g., unable to write clearly or
walk)
We found this trial at
1
site
2450 West Charleston Boulevard
Las Vegas, Nevada 89102
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials